高雄醫學大學圖書館 |

Phase I oncology drug development

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Phase I oncology drug development/ edited by Timothy A. Yap, Jordi Rodon, David S. Hong.
其他作者:	Hong, David S.
出版者:	Cham :Springer International Publishing : : 2020.,
面頁冊數:	x, 352 p. :ill., digital ; : 24 cm.;
提要註:	This book provides a detailed review of how oncology drug development has changed over the past decade, and serves as a comprehensive guide for the practicalities in setting up phase I trials. The book covers strategies to accelerate the development of novel antitumor compounds from the laboratory to clinical trials and beyond through the use of innovative mechanism-of-action pharmacodynamic biomarkers and pharmacokinetic studies. The reader will learn about all aspects of modern phase I trial designs, including the incorporation of precision medicine strategies, and approaches for rational patient allocation to novel anticancer therapies. Circulating biomarkers to assess mechanisms of response and resistance are changing the way we are assessing patient selection and are also covered in this book. The development of the different classes of antitumor agents are discussed, including chemotherapy, molecularly targeted agents, immunotherapies and also radiotherapy. The authors also discuss the lessons that the oncology field has learnt from the development of hematology-oncology drugs and how such strategies can be carried over into therapies for solid tumors. There is a dedicated chapter that covers the specialized statistical approaches necessary for phase I trial designs, including novel Bayesian strategies for dose escalation. This volume is designed to help clinicians better understand phase I clinical trials, but would also be of use to translational researchers (MDs and PhDs), and drug developers from academia and industry interested in cancer drug development. It could also be of use to phase I trial study coordinators, oncology nurses and advanced practice providers. Other health professionals interested in the treatment of cancer will also find this book of great value.
Contained By:	Springer Nature eBook
標題:	Radiotherapy. -
電子資源:	https://doi.org/10.1007/978-3-030-47682-3
ISBN:	9783030476823

Phase I oncology drug development
Phase I oncology drug development[electronic resource] /edited by Timothy A. Yap, Jordi Rodon, David S. Hong. - Cham :Springer International Publishing :2020. - x, 352 p. :ill., digital ;24 cm.

Paradigm shift in oncology drug development -- Practicalities in setting up phase I trials -- Optimizing the preclinical development of antitumor agents for entry into phase I trials -- Considerations for the development of novel chemotherapies in phase I trials -- Considerations for the development of novel targeted agents in phase I trials -- Development of immunotherapeutic strategies in early phase clinical trials -- Assessment of radiotherapeutic strategies in phase I trials -- Development of combinatorial strategies in phase I trials -- Novel trial designs for early phase clinical trials -- Incorporating pharmacokinetic strategies for phase I trials -- Development of pharmacodynamic biomarkers for phase I trials -- Efficacy considerations for Phase I trials -- Incorporating precision medicine into Phase I clinical trials -- Molecular profiling of patients for clinical trials -- Incorporating circulating biomarkers into clinical trials -- Statistical considerations for early phase clinical trials -- Lessons from hematology for solid tumor drug development.

This book provides a detailed review of how oncology drug development has changed over the past decade, and serves as a comprehensive guide for the practicalities in setting up phase I trials. The book covers strategies to accelerate the development of novel antitumor compounds from the laboratory to clinical trials and beyond through the use of innovative mechanism-of-action pharmacodynamic biomarkers and pharmacokinetic studies. The reader will learn about all aspects of modern phase I trial designs, including the incorporation of precision medicine strategies, and approaches for rational patient allocation to novel anticancer therapies. Circulating biomarkers to assess mechanisms of response and resistance are changing the way we are assessing patient selection and are also covered in this book. The development of the different classes of antitumor agents are discussed, including chemotherapy, molecularly targeted agents, immunotherapies and also radiotherapy. The authors also discuss the lessons that the oncology field has learnt from the development of hematology-oncology drugs and how such strategies can be carried over into therapies for solid tumors. There is a dedicated chapter that covers the specialized statistical approaches necessary for phase I trial designs, including novel Bayesian strategies for dose escalation. This volume is designed to help clinicians better understand phase I clinical trials, but would also be of use to translational researchers (MDs and PhDs), and drug developers from academia and industry interested in cancer drug development. It could also be of use to phase I trial study coordinators, oncology nurses and advanced practice providers. Other health professionals interested in the treatment of cancer will also find this book of great value.

ISBN: 9783030476823

Standard No.: 10.1007/978-3-030-47682-3doiSubjects--Topical Terms:

254565
Radiotherapy.

LC Class. No.: RC271.C5

Dewey Class. No.: 615.798

Phase I oncology drug development
LDR:03855nam a2200325 a 4500 001 338407
003 DE-He213
005 20210128154723.0
006 m d
007 cr nn 008maaau
008 210622s2020 sz s 0 eng d
020 $a 9783030476823 $q (electronic bk.)
020 $a 9783030476816 $q (paper)
024 7 $a 10.1007/978-3-030-47682-3 $2 doi
035 $a 978-3-030-47682-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.C5
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 615.798 $2 23
090 $a RC271.C5 $b P536 2020
245 0 0 $a Phase I oncology drug development $h [electronic resource] / $c edited by Timothy A. Yap, Jordi Rodon, David S. Hong.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a x, 352 p. : $b ill., digital ; $c 24 cm.
505 0 $a Paradigm shift in oncology drug development -- Practicalities in setting up phase I trials -- Optimizing the preclinical development of antitumor agents for entry into phase I trials -- Considerations for the development of novel chemotherapies in phase I trials -- Considerations for the development of novel targeted agents in phase I trials -- Development of immunotherapeutic strategies in early phase clinical trials -- Assessment of radiotherapeutic strategies in phase I trials -- Development of combinatorial strategies in phase I trials -- Novel trial designs for early phase clinical trials -- Incorporating pharmacokinetic strategies for phase I trials -- Development of pharmacodynamic biomarkers for phase I trials -- Efficacy considerations for Phase I trials -- Incorporating precision medicine into Phase I clinical trials -- Molecular profiling of patients for clinical trials -- Incorporating circulating biomarkers into clinical trials -- Statistical considerations for early phase clinical trials -- Lessons from hematology for solid tumor drug development.
520 $a This book provides a detailed review of how oncology drug development has changed over the past decade, and serves as a comprehensive guide for the practicalities in setting up phase I trials. The book covers strategies to accelerate the development of novel antitumor compounds from the laboratory to clinical trials and beyond through the use of innovative mechanism-of-action pharmacodynamic biomarkers and pharmacokinetic studies. The reader will learn about all aspects of modern phase I trial designs, including the incorporation of precision medicine strategies, and approaches for rational patient allocation to novel anticancer therapies. Circulating biomarkers to assess mechanisms of response and resistance are changing the way we are assessing patient selection and are also covered in this book. The development of the different classes of antitumor agents are discussed, including chemotherapy, molecularly targeted agents, immunotherapies and also radiotherapy. The authors also discuss the lessons that the oncology field has learnt from the development of hematology-oncology drugs and how such strategies can be carried over into therapies for solid tumors. There is a dedicated chapter that covers the specialized statistical approaches necessary for phase I trial designs, including novel Bayesian strategies for dose escalation. This volume is designed to help clinicians better understand phase I clinical trials, but would also be of use to translational researchers (MDs and PhDs), and drug developers from academia and industry interested in cancer drug development. It could also be of use to phase I trial study coordinators, oncology nurses and advanced practice providers. Other health professionals interested in the treatment of cancer will also find this book of great value.
650 0 $2 96060 $a Radiotherapy. $3 254565
650 0 $2 96060 $a Oncology. $3 273823
650 0 $2 96060 $a Medicine. $3 219985
650 0 $2 96060 $a Drug development. $3 232902
650 0 $2 96060 $a Cancer $x Chemotherapy. $3 237030
650 0 $a Antineoplastic agents $x Design. $3 306871
700 1 $a Hong, David S. $3 466460
700 1 $a Rodon, Jordi. $3 466459
700 1 $a Yap, Timothy A. $3 466458
710 2 $2 97100 $a SpringerLink (Online service) $3 255133
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-030-47682-3
950 $a Medicine (SpringerNature-11650)